Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
Location: United States, California, South San Francisco
Employees: 51-200
Total raised: $207M
Founded date: 2015
Investors 4
| Date | Name | Website |
| - | Logos Capi... | logoscapit... |
| - | Agent Capi... | agentcapit... |
| 20.06.2023 | Valiance | valiance-a... |
| - | Menlo Vent... | menlovc.co... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 03.03.2020 | Series C | $100M | - |
| 16.07.2018 | Series B | $62M | - |
| 18.02.2016 | Series A | $45M | - |
Mentions in press and media 13
| Date | Title | Description |
| 15.10.2024 | Arda Therapeutics: Targeted Cell Depletion Therapy Company Raises $43 Million (Series A) | Arda Therapeutics, a pioneer in targeted cell depletion therapies for chronic diseases, announced the successful completion of a $43 million Series A funding round. This funding round was led by existing investor Andreessen Horowitz (a16z B... |
| 12.03.2024 | Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis | - |
| 25.01.2023 | Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering | /EIN News/ -- SOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibr... |
| 24.01.2023 | Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering | - |
| 12.07.2022 | Can positive but exploratory data entice investors to $150M raise in a bear market? Pliant will find out | Pliant Therapeutics is traveling down the well-trodden path from positive data to public offering — and it’s going to Nasdaq with a sizable ask. On the back of early data for its TGF-β inhibitor in idiopathic pulmonar... |
| 12.07.2022 | Pliant Therapeutics Announces Pricing of Upsized $200.0 Million Public Offering | SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today an... |
| 03.03.2020 | Pliant Therapeutics Raises $100M in Series C | SOUTH SAN FRANCISCO, CA, Pliant Therapeutics today announced that it has raised $100 million in a Series C financing. >> Click here for more funding data on Pliant Therapeutics >> To export Pliant Therapeutics funding data t... |
| 17.07.2018 | Pliant Therapeutics Inks $62M Series B | SOUTH SAN FRANCISCO, CA, Pliant Therapeutics, Inc. today announced that it has raised $62 million in a Series B financing. >> Click here for more funding data on Pliant Therapeutics >> To export Pliant Therapeutics funding d... |
| 17.07.2018 | Term Sheet — Tuesday, July 17 | CULTURE CLASH Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop UBER’S TRIALS & TRIBULATIONS: Fortune’s Brainstorm Tech conference kicked off yesterday with a conversation betw... |
| 16.07.2018 | Pliant Therapeutics Raises $62M in Series B Financing | Pliant Therapeutics, Inc., a South San Francisco, CA-based biotechnology company targeting the key biological pathways driving fibrosis, raised $62m in Series B financing. The round was led by Cowen Healthcare Investments, with participatio... |
Show more